香港交易及結算所有限公司及香港聯合交易所有限公司對本公告的內容概不負責，對其準確性 或完整性亦不發表任何聲明，並明確表示，概不對因本公告全部或任何部分內容而產生或因倚 賴該等內容而引致之任何損失承擔任何責任。 本公告僅供參考，並不構成收購、購買或認購本公司證券的邀請或要約。 本公告不會於美國或其境內直接或間接分發。本公告並不構成或組成於美國購買或認購證券之 任何要約或招攬之一部分。本公告所述之本公司股份並未亦將不會根據1933年美國證券法（經 修訂）（「證券法」）登記，且除非已根據證券法之登記規定登記或獲豁免登記，否則將不得於美 國提呈發售或出售。本公司股份將不會於美國公開發售。 CONCORD HEALTHCARE GROUP CO., LTD. 美中嘉和醫學技術發展集團股份有限公司 董事會欣然宣佈，配售協議所載全部條件已獲達成且配售事項已於2025年7月29 日按照配售協議的條款及條件完成。於本公告日期，合共48,723,600股配售股份 已由配售代理根據配售協議的條款及條件按每股配售股份5.54港元之配售價向不 少於六名承配人成功配售，相當於緊接完成前已發行H股數目的約18.38%及已發 行股份數目的約 ...

Market Overview - The Hong Kong stock market showed volatility, with the Hang Seng Index closing at 25,130.03 points, up 0.54% or 135.89 points, with a total turnover of HKD 266.07 billion [1] - The Hang Seng China Enterprises Index rose 0.39% to 9,075.6 points, while the Hang Seng Tech Index increased by 0.38% to 5,606.83 points [1] Blue Chip Performance - BYD (01211) saw a significant increase of 5.09%, closing at HKD 134.2, contributing 37.78 points to the Hang Seng Index [2] - In the first half of 2023, BYD's domestic sales exceeded 2.113 million units, a year-on-year increase of 31.5%, while overseas sales reached 472,000 units, up 128.5% [2] - Other notable blue chips included Xinyi Glass (00868) up 7.23%, Zhongsheng Holdings (00881) up 6.15%, while New Oriental (09901) and Bank of China Hong Kong (02388) saw declines of 4.92% and 3.5% respectively [2] Sector Highlights - Coal stocks surged, with Mongolian Coking Coal (00975) up 11.55% and Yancoal Australia (01171) up 9.53%, driven by rumors of capacity control measures in the coal industry [3][4] - Infrastructure stocks performed strongly, with China Communications Construction (01800) rising 7.57% and China Railway Construction (01186) up 6.03% [4] - The launch of the Yarlung Tsangpo River downstream hydropower project, with an investment of approximately CNY 1.2 trillion, is expected to boost infrastructure investment [5] Commodity and Material Stocks - Non-ferrous metal stocks continued to rise, with Ganfeng Lithium (01772) up 8.94% and Luoyang Molybdenum (03993) up 7.12%, supported by upcoming policies aimed at stabilizing growth in key industries [6] - The photovoltaic sector was active, with Kaisa New Energy (01108) rising 8% and GCL-Poly Energy (03800) up 6.67%, as supply-side reforms are anticipated to improve industry conditions [7] Notable Stock Movements - China Longgong (03339) surged 15.83% after announcing a significant profit increase forecast for the first half of 2025 [8] - Fufeng Group (00546) rose 10.8% on expectations of a substantial profit increase due to higher sales and lower raw material costs [9] - Lijun Pharmaceutical (01513) reached a new high, up 9.37%, following positive clinical trial results for a new drug [10] - Harbin Electric (01133) climbed 8.14% after announcing a profit forecast that exceeded expectations [11] - Meizhong Jiahe (02453) faced pressure, down 6%, due to a planned share placement at a discount [12]

Group 1: Market Developments - Hong Kong Stock Exchange will lower the minimum price fluctuation for stocks starting August 4, 2025, following successful market rehearsals and regulatory approvals [1] - The Hang Seng Index's ADR closed at 24,987.99 points, down 6.15 points or 0.02% [3] Group 2: Index Adjustments - The Hang Seng Index announced changes to the calculation method of the Hang Seng Hong Kong Stock Connect Innovative Drug Selection Index, effective from the index review on June 30, 2025 [2] Group 3: Company Earnings - Cathay Pacific reported a 23.3% year-on-year increase in passenger numbers, carrying approximately 2.9 million passengers in June 2025 [8] - China Longgong expects a significant increase in net profit for the first half of 2025, estimated between RMB 590 million and RMB 665 million, representing a year-on-year increase of 29% to 45% [11] - Meitu Company anticipates a 65% to 72% year-on-year growth in adjusted net profit for the first half of 2025 [10] - Hengtou Securities expects a net profit of approximately RMB 239 million for the first half of 2025, a significant increase from RMB 53.87 million in the same period last year [14] - Huiri Group forecasts a consolidated profit of approximately HKD 250 million for the first half of 2025, up from HKD 37 million in the previous year [15] - Harbin Electric anticipates a net profit of approximately RMB 1.02 billion for the first half of 2025, a substantial increase from RMB 523 million in the same period last year [21] Group 4: Strategic Initiatives - Multiple departments released implementation details for cross-border asset management pilot business in Hainan Free Trade Port, allowing foreign investors to invest in various financial products [6] - Dongyangguang Jiangsu Pharmaceutical and Dongyangguang Pharmaceutical's merger agreement was approved by shareholders, with the new entity expected to be listed on August 7, 2025 [13] - Global New Materials International's acquisition of Merck's surface solutions business was approved by a special shareholder meeting, with a transaction value of EUR 665 million [17] Group 5: Industry Trends - GGII reported that China's power battery installation capacity reached approximately 288.1 GWh in the first half of 2025, a year-on-year increase of 44% [5] - The key product DB-1310 from InnoCare Pharma has received fast track designation from the FDA for treating advanced non-small cell lung cancer [20]

Group 1 - The core announcement is that Meizhong Jiahe plans to raise approximately HKD 270 million through the placement of 48,723,600 new H shares, with a net amount of about HKD 260 million after expenses [1] - The placement price is set at HKD 5.54 per share, representing a discount of approximately 16.9% to the closing price of HKD 6.67 on July 21, 2025, and a discount of about 19.9% to the average closing price of HKD 6.92 over the previous five trading days [1] - The newly issued shares will account for approximately 6.6% of the existing issued share capital and about 6.2% of the enlarged share capital after the placement [1] Group 2 - The funds raised will be allocated for the construction of Shanghai Taihe Cheng Cancer Hospital, support for medical AI business needs, repayment of financial institution loans, and to supplement working capital [1] - The issuance is conducted under a general mandate granted by the shareholders' meeting and is expected to be completed on the second business day after obtaining listing approval, no later than July 29, 2025 [1]

Core Viewpoint - 美中嘉和 (02453.HK) has entered into a placement agreement with Guotai Junan International to issue 48.72 million shares at a price of HKD 5.54 per share, representing approximately 18.38% of the existing H shares and 6.63% of the total issued shares as of the announcement date [1][2] Group 1: Placement Details - The placement involves 48.72 million shares, which will be issued under a general authorization [1] - The placement shares will account for approximately 15.52% of the enlarged issued H shares and about 6.22% of the total issued shares after the placement [1] Group 2: Use of Proceeds - The total expected proceeds from the placement are approximately HKD 270 million, with a net amount of about HKD 259 million [2] - The net proceeds will be allocated as follows: - Approximately HKD 77.63 million (30%) for the construction of Shanghai Taihe Cheng Tumor Hospital, expected to be fully utilized by June 30, 2026 [2] - Approximately HKD 38.82 million (15%) to support the company's medical AI business, including operational and R&D expenses, also expected to be fully utilized by June 30, 2026 [2] - Approximately HKD 64.69 million (25%) for repaying loans from financial institutions, including principal and interest for working capital loans and fixed asset loans, expected to be fully utilized by June 30, 2026 [2] - Approximately HKD 77.63 million (30%) for replenishing the company's working capital and general corporate purposes, expected to be fully utilized by June 30, 2026 [2]

香港交易及結算所有限公司及香港聯合交易所有限公司對本公告的內容概不負責，對其準確性 或完整性亦不發表任何聲明，並明確表示，概不對因本公告全部或任何部分內容而產生或因倚 賴該等內容而引致之任何損失承擔任何責任。 本公告僅供參考，並不構成收購、購買或認購本公司證券的邀請或要約。 本公告不會於美國或其境內直接或間接分發。本公告並不構成或組成於美國購買或認購證券之 任何要約或招攬之一部分。本公告所述之本公司股份並未亦將不會根據1933年美國證券法（經 修訂）（「證券法」）登記，且除非已根據證券法之登記規定登記或獲豁免登記，否則將不得於美 國提呈發售或出售。本公司股份將不會於美國公開發售。 CONCORD HEALTHCARE GROUP CO., LTD. 美中嘉和醫學技術發展集團股份有限公司 （於中華人民共和國註冊成立的股份有限公司） （股份代號：2453） 根據一般授權按配售協議配售新股份 獨家整體協調人、配售代理及資本市場中介人 於2025年7月22日（交易時段前），本公司與配售代理訂立配售協議。據此，配 售代理已有條件同意擔任本公司獨家配售代理，並以盡最大努力基準促使不少 於六(6)名承配人（該等承配人及其最 ...

Core Viewpoint - Meizhong Jiahe (2453.HK) has achieved a significant breakthrough in the treatment of choroidal malignant melanoma by successfully completing the first proton therapy in China, which preserves the patient's eye and vision, filling a treatment gap in the country [1][2]. Group 1: Treatment Innovation - The proton therapy using "pencil beam scanning" technology allows for high-dose radiation to be precisely focused on the tumor while minimizing damage to surrounding critical structures, marking a shift from destructive to functional treatment [1][2]. - Traditional treatment methods primarily involved enucleation, which resulted in permanent blindness and facial disfigurement for patients [1]. Group 2: Patient Outcomes - The first patient treated, a 45-year-old male from Hunan, experienced a significant improvement in vision from 0.1 to 0.4 within 48 hours post-treatment, with tumor markers decreasing by 90% and no complications such as corneal ulcers or retinal detachment [2]. - The patient expressed satisfaction with the treatment, stating he was able to retain his eye and continue working, contrasting with his initial expectation of undergoing enucleation [2]. Group 3: Market Potential - Proton therapy is recommended as a first-line treatment for choroidal melanoma in the 2024 NCCN guidelines, providing evidence-based support for eye-preserving strategies [2]. - With approximately 2,500 new cases of choroidal malignant melanoma diagnosed annually in China, Meizhong Jiahe's advancements in this field are expected to benefit domestic patients and create substantial market opportunities for the company [2].

自願公告 完成全國首例脈絡膜惡性黑色素瘤質子治療 本公告乃由美中嘉和醫學技術發展集團股份有限公司（「本公司」）董事會（「董事 會」）自願刊發。 董事會欣然宣佈，本公司子公司廣州泰和腫瘤醫院於2025年7月11日，成功完成 全國首例脈絡膜惡性黑色素瘤質子治療。 脈絡膜惡性黑色素瘤是一種常見眼內惡性腫瘤，傳統標準治療方案是眼球摘除 術，這雖然能夠有效控制局部病灶，但不可避免地造成患者的永久性失明和面部 外觀改變，仍有威脅生命的風險。 香港交易及結算所有限公司及香港聯合交易所有限公司對本公告的內容概不負責，對其準確性 或完整性亦不發表任何聲明，並明確表示，概不對因本公告全部或任何部分內容而產生或因倚 賴該等內容而引致之任何損失承擔任何責任。 CONCORD HEALTHCARE GROUP CO., LTD. 美中嘉和醫學技術發展集團股份有限公司 （於中華人民共和國註冊成立的股份有限公司） （股份代號：2453） 於本公告日期，董事會包括(i)執行董事楊建宇博士、付驍女士及常亮先生；(ii)非 執行董事王雷先生、宋清寶先生及施波濤先生；及(iii)獨立非執行董事李雪梅女 士、孫延生先生及吳國賢先生。 廣州泰和腫瘤醫 ...

香港交易及結算所有限公司及香港聯合交易所有限公司對本公告的內容概不負責，對其準確性 或完整性亦不發表任何聲明，並明確表示，概不對因本公告全部或任何部分內容而產生或因倚 賴該等內容而引致之任何損失承擔任何責任。 CONCORD HEALTHCARE GROUP CO., LTD. 茲提述美中嘉和醫學技術發展集團股份有限公司（「本公司」，連同其附屬公司， 「本集團」）日期為2025年4月25日的截至2024年12月31日止年度之年度報告（「年 報」）。除文義另有所指外，本公告所用詞彙與年報所界定者具有相同涵義。 除年報所載資料外，本公司謹此進一步提供以下有關質子治療服務的補充資料。 質子治療服務為本公司具有高增長潛力的核心業務，有望與本公司其他業務產生 協同效應。為盡快開展質子治療服務，本公司及時調整了其他醫療服務業務的運 營策略，並優化了廣州醫院的成本結構，包括： 1 (1) 本公司關閉或縮減了廣州醫院的部分虧損業務，並減少人員配置。廣州醫院 的僱員人數由截至2023年12月31日的295人減少至截至2024年12月31日的 252人。該調整直接影響了廣州醫院的服務能力，導致2024年廣州醫院接收 和治療的患者 ...

香港交易及結算所有限公司及香港聯合交易所有限公司對本公告的內容概不負責，對其準確性 或完整性亦不發表任何聲明，並明確表示，概不對因本公告全部或任何部分內容而產生或因倚 賴該等內容而引致之任何損失承擔任何責任。 本公告乃由美中嘉和醫學技術發展集團股份有限公司（「本公司」，連同其附屬公 司，「本集團」）自願作出。茲提述本公司日期為2024年7月31日有關終止投票委託 安排的公告（「該公告」）。除另有說明外，本公告所用詞彙與該公告所界定者具有 相同涵義。 於2025年6月24日，本公司獲上海信荷（持有本公司13,333,332股內資股股份）通 知，其於2025年6月24日召開的合夥人會議審議並批准，為了進一步優化上海信 荷的經營決策方式，上海醫學之星將不再為上海信荷的有限合夥人，且楊博士最 終控制的上海信複企業管理中心（有限合夥）將不再為上海信荷的普通合夥人。變 更後上海信荷的各合夥人均獨立於楊博士及其控制的實體及彼等的關連人士（定 義見上市規則）。 因此，上海信荷將不再是本公司控股股東（定義見上市規則）的成員。於本公告 日期，楊博士及其控制的實體，包括Morgancreek Investment Holdings ...